CH5183284
CAS No. 1265229-25-1
CH5183284 ( Debio-1347; Debio 1347; Debio1347; CH5183284 )
产品货号. M17232 CAS No. 1265229-25-1
CH5183284 is a selective and orally available FGFR inhibitor, which is for FGFR1(IC50=9.3 nM), FGFR2(IC50=7.6 nM), FGFR3(IC50=290), and FGFR4(IC50=22 nM), respectively.
纯度: 95%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥316 | 有现货 |
|
10MG | ¥583 | 有现货 |
|
25MG | ¥1021 | 有现货 |
|
50MG | ¥1604 | 有现货 |
|
100MG | ¥2989 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CH5183284
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CH5183284 is a selective and orally available FGFR inhibitor, which is for FGFR1(IC50=9.3 nM), FGFR2(IC50=7.6 nM), FGFR3(IC50=290), and FGFR4(IC50=22 nM), respectively.
-
产品描述Debio-1347, also known as FF284 and CH5183284, is an orally bioavailable inhibitor of the fibroblast growth factor receptor subtypes 1 (FGFR-1), 2 (FGFR-2) and 3 (FGFR-3), with potential antineoplastic activity. FGFR inhibitor debio 1347 binds to and inhibits FGFR-1, -2, and -3, which result in the inhibition of FGFR-mediated signal transduction pathways. This leads to the inhibition of both tumor cell proliferation and angiogenesis, and causes cell death in FGFR-overexpressing tumor cells.
-
同义词Debio-1347; Debio 1347; Debio1347; CH5183284
-
通路Endocrinology/Hormones
-
靶点Estrogen Receptor/ERR
-
受体FGFR1; FGFR2; FGFR3; FGFR4
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1265229-25-1
-
分子量356.38
-
分子式C20H16N6O
-
纯度95%
-
溶解度DMSO : 25 mg/mL. 70.15 mM;
-
SMILESCc1nc2c([nH]1)cc(cc2)n1c(c(cn1)C(=O)c1cc2ccccc2[nH]1)N
-
化学全称(5-amino-1-(2-methyl-1H-benzo[d]imidazol-6-yl)-1H-pyrazol-4-yl)(1H-indol-2-yl)methanone
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Nakanishi Y, et al. Mol Y Ther. 2014, 13(11), 2547-2558.
产品手册
关联产品
-
SR 19881
SR 19881 is a full agonist of ERRγ(EC50 value of 0.39 μM in a binding assay and an EC50 value of 4.7 μM in a cell-based assay).?
-
Toremifene citrate
Toremifene Citrate(NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.
-
WAY-200070
WAY-200070 is a potent, highly selective ERβ agonist with IC50 of 3 nM, displays 68-fold selectivity over ERα (IC50=260 nM).